April 2026
Macromolecular Drug Discovery: Trends Shaping the Biopharma Industry
Macromolecular medicines are changing how scientists think about drug discovery. Oligonucleotides, RNA therapeutics, and other complex biologics allow researchers to intervene directly at the level of gene expression. Instead of targeting downstream proteins, these therapies can silence, regulate, or modify the genes driving disease. The TIDES industry are now looking to the future. Getting large therapeutic molecules into the right tissue remains one of the most complex problems in today’s landscape. However, this is also where some of the most exciting innovations are happening. So, what can we expect from the future of macromolecular drug discovery? This article dives into some of the focal points of the industry today.
#macromolecules #drugdiscovery #drugdelivery #tides
Why is drug delivery central to macromolecular therapeutics?
Macromolecular drugs behave very differently from traditional small molecules. siRNA, ASOs, and RNA-based medicines are larger and, thus, more complex in nature. They also face the challenge of being more susceptible to degradation, often being unable to cross biological barriers or cell membranes without assistance.
This is why the tides industry are seeking new delivery technologies - a critical area of research today. Scientists are developing platforms designed to guide these molecules through the body, preventing degradation and improving uptake in specific tissues. Some of the key focal strategies include:
- Lipid nanoparticle (LNP) delivery systems
- Ligand-targeted oligonucleotide conjugates
- Antibody or nanobody-based delivery platforms
- Peptide-mediated RNA delivery technologies
Taken together, these new approaches are expanding the reach of RNA therapeutics and enabling us to target a much broader range of diseases.
Overcoming the Blood-Brain Barrier for CNS Drug Delivery
A significant challenge within macromolecular drug delivery is the blood-brain barrier (BBB). While the BBB protects the brain from harmful substances, this protection doubles as a prevention for most therapeutic molecules - stopping them from entering the central nervous system. Historically, this has made neurological diseases particularly difficult to treat with biologics or RNA-based therapies.
So, how will this be overcome?
Research is homing in on the development of receptor-mediated delivery systems. These systems are proposed to be capable of transporting therapeutics across the BBB – a huge win for the industry if successful. One of the most promising targets is the transferrin receptor (TfR). By attaching oligonucleotides or antibodies to molecules that bind this receptor, scientists can effectively shuttle therapeutics into brain tissue. Early studies have demonstrated broad brain distribution and meaningful gene knockdown following systemic dosing, highlighting the potential for RNA therapeutics to treat neurological conditions such as:
- Alzheimer’s disease
- Parkinson’s disease
- Rare genetic neurological disorders
If these delivery technologies continue to translate successfully, they could significantly expand the impact of macromolecular medicines in CNS disease.
How are RNA therapeutics expanding beyond the liver?
Many successful RNA therapeutic stories came from those that targeted the liver, largely due to the efficiency of GalNAc-based delivery systems. However, the majority of diseases occur outside of the liver, and so the industry must pivot to accelerate the next big breakthrough. The focus has turned towards solving one of the next major challenges in RNA drug development, extrahepatic delivery. Researchers are developing new technologies capable of delivering oligonucleotides and RNA therapeutics to tissues such as:
- Muscle
- Adipose tissue
- Kidney
- Central nervous system
- Immune cells
Emerging delivery platforms, including selective organ-targeting lipid nanoparticles, peptide ligands, and receptor-targeted siRNA systems, are beginning to demonstrate promising results in preclinical studies. If successful, these advances could dramatically expand the range of diseases treatable with RNA medicines, including metabolic diseases, kidney disorders, neuromuscular conditions, and obesity.
How are emerging AI and Machine Learning changing RNA Drug Delivery?
Another important trend shaping macromolecular drug discovery is the growing role of artificial intelligence and machine learning in delivery design. Researchers are increasingly using computational tools to identify receptors on target cells, predict internalization behavior, and design optimized targeting ligands. Some emerging approaches combine single-cell RNA sequencing with deep learning models to identify cell-surface receptors and design ligands that bind efficiently to those targets. Other platforms are using high-throughput in vivo screening and machine learning to evaluate thousands of delivery candidates and map their biodistribution across tissues. These technologies are helping accelerate discovery and enabling the development of precision delivery systems tailored to specific tissues and diseases.
What’s in store for the next generation of macromolecular medicines?
As delivery platforms continue to improve, they are enabling entirely new therapeutic approaches. Researchers are now exploring technologies such as:
- In vivo CAR T cell generation using lipid nanoparticles
- Non-viral DNA delivery platforms for sustained protein expression
- Tissue-selective RNAi therapies
- Targeted gene silencing in organs such as the kidney
These innovations illustrate how delivery platforms are becoming more than supporting technologies. They are increasingly shaping the design of next-generation therapies and, therefore, changing the industry with them.
How can TIDES USA 2026 help you explore the future of macromolecular Drug Delivery?
The rapid progress in oligonucleotide therapeutics, RNA delivery technologies, and macromolecular drug discovery is driving new conversations across the biopharma industry. Many of these developments will be explored in the Delivery of Macromolecules track at TIDES USA, where researchers are presenting new work on:
- CNS delivery of oligonucleotides
- Extrahepatic RNA targeting strategies
- Next-generation delivery platforms
- AI-enabled ligand and peptide discovery
As macromolecular medicines continue to expand across therapeutic areas, innovations in delivery will play a critical role in unlocking their full potential. For scientists working in RNA therapeutics, gene silencing, and advanced biologics, it’s an area of the field that’s moving quickly - and one that is shaping the future of drug discovery.
Will you be part of the discussions changing the industry?
